Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial

Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial
复制标题

DOI:
10.1016/s0140-6736(10)61997-6
复制
发表时间:
2010-11-01
期刊:
影响因子:
168.9
通讯作者:
Plummer, Francis A.
Plummer, Francis A.
中科院分区:
医学1区
文献类型:
--
作者:
Lester, Richard T.;Ritvo, Paul;Plummer, Francis A.

文献摘要

被引文献

相似文献

背景已经建议将移动(蜂窝)电话通信作为改进健康服务交付的一种方法。然而,在资源有限的情况下,关于移动卫生技术对患者结局的影响的数据有限。我们的目的是评估肯尼亚医护人员和开始抗逆转录病毒治疗的患者之间的手机通信是否改善了药物依从性和抑制血浆HIV-1 RNA载量。方法Weltel Kenya1是一项多点随机临床试验,在肯尼亚的三家诊所开始抗逆转录病毒治疗(ART)。患者通过简单的随机化(1:1)与手机短消息服务(SMS)干预或标准护理的随机数生成程序进行随机化。干预组的患者每周都会收到诊所护士发来的短信,并被要求在48小时内回复。随机化、实验室分析和分析都是由研究人员进行的,但研究参与者和诊所工作人员没有被掩盖进行治疗。主要结果是自我报告的抗逆转录病毒治疗依从性(在过去30天内,在6个月和12个月的随访中,95%的处方剂量)和血浆HIV-1病毒RNA载量受到抑制(
Background Mobile (cell) phone communication has been suggested as a method to improve delivery of health services. However, data on the effects of mobile health technology on patient outcomes in resource-limited settings are limited. We aimed to assess whether mobile phone communication between health-care workers and patients starting antiretroviral therapy in Kenya improved drug adherence and suppression of plasma HIV-1 RNA load.Methods WelTel Kenya1 was a multisite randomised clinical trial of HIV-infected adults initiating antiretroviral therapy (ART) in three clinics in Kenya. Patients were randomised (1:1) by simple randomisation with a random number generating program to a mobile phone short message service (SMS) intervention or standard care. Patients in the intervention group received weekly SMS messages from a clinic nurse and were required to respond within 48 h. Randomisation, laboratory assays, and analyses were done by investigators masked to treatment allocation; however, study participants and clinic staff were not masked to treatment. Primary outcomes were self-reported ART adherence (>95% of prescribed doses in the past 30 days at both 6 and 12 month follow-up visits) and plasma HIV-1 viral RNA load suppression (